Cargando…
Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments
Heart failure is a common complication in patients with diabetes, and people with both conditions present a worse prognosis. Sodium–glucose cotransporter 2 inhibitors (SGLT2Is) increase urinary glucose excretion, improving glycaemic control. In type 2 diabetes (T2D), some SGLT2Is reduce major cardio...
Autor principal: | Tamargo, Juan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Radcliffe Cardiology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523047/ https://www.ncbi.nlm.nih.gov/pubmed/31131034 http://dx.doi.org/10.15420/ecr.2018.34.2 |
Ejemplares similares
-
Corrigendum to: Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments
por: Tamargo, Juan
Publicado: (2019) -
When Should We Start Sodium–Glucose Co-transporter Inhibitors in Patients with Heart Failure? The Importance of Early Intervention
por: Iguchi, Moritake, et al.
Publicado: (2023) -
Hidden in Heart Failure
por: Cannie, Douglas Ewan, et al.
Publicado: (2019) -
Cardiac Resynchronisation Therapy and Cellular Bioenergetics: Effects Beyond Chamber Mechanics
por: Antoniou, Christos-Konstantinos, et al.
Publicado: (2019) -
Chagas Disease and Heart Failure: An Expanding Issue Worldwide
por: Martinez, Felipe, et al.
Publicado: (2019)